Mitochondria are virtually ubiquitous organelles in animal cells, containing the only endogenous extrachromosomal DNA. In humans this 16.6 kb circular genome (mtDNA) encodes some 13 polypeptides, 2 rRNAs and 22 tRNAs, all of which are involved in mitochondrial biogenesis and ATP production. The nuclear genome exerts close control over the mitochondrial genome, encoding approximately 1000 proteins which are imported and active in mitochondria.
Mitochondrial disorders principally affect tissues with high ATP turnover, such as muscle and brain. They cannot be effectively treated and are often fatal. The mitochondrial genome is responsible for a disproportionately high occurrence of mitochondrial disease, for which over 50 pathogenic mutations and rearrangements have been identified. 1 A recent study in the north-east of England by Chinnery and Turnbull (personal communication) has shown that the occurrence of pathological mitochondrial mutations in this population is at least 1/8000 with an incidence of 1/15 000 for mitochondrial disease manifestation. This becomes significant when combined with the observation that one in every hundred individuals is born with a serious genetic defect, 2 meaning that 1.25% of all genetic disorders may derive from the mitochondrial genome.
Mitochondrial genetics are complicated by the existence of 10 3 -10 4 copies of mtDNA in a typical cell. Heteroplasmic populations consisting of two or more species of mtDNA can coexist in mitochondrial disorders, with different thresholds of phenotypic presentation, depending upon tissue type and ATP requirements. Alterations in the proportions of heterogeneic mtDNA can thus eliminate or exacerbate a phenotype within tissues and individual cells.
The approaches towards gene therapy of mitochondrial diseases are:
(1) to import a nuclear expressed protein or RNA into mitochondria; (2) to directly replace a gene in the mitochondrial genome; and (3) to limit replication or transcription of mutated mtDNA to an extent that it is eliminated or severely depleted with respect to wild-type mtDNA.
dria, the protein import system or possible mechanisms involved in the import of small RNAs, are potential routes for internalisation of therapeutic molecules. Using conventional gene therapy vectors, several groups have demonstrated gene correction of nuclear encoded proteins which are post-translationally imported into the mitochondrion, such as ornithine transcarbamylase (OTC). These proteins generally contain a positively charged N-terminal presequence, which directs them to the mitochondria and permits uptake by the protein import machinery. Attachment of presequences to nonmitochondrial proteins promotes mitochondrial import, 4 suggesting that nuclear gene expression may provide an avenue for the correction of disorders due to mtDNA encoded proteins. However, these highly hydrophobic proteins are tightly folded and may be unable to undergo the conformational changes required for import. Attempts to correct mutations at the level of the mitochondrial genome have proven even more complex. Firstly, genes inserted into the mitochondrial genome must be modified for translation using the altered genetic code in mitochondria, modification of the entire mitochondrial genome is not a straightforward procedure, 5 and finally, the altered construct must be transferred into mitochondria. 3 The idea of using the protein import machinery for internalisation of nucleic acids into the mitochondria was first exploited by Vestweber and Schatz, 6 who coupled 24 bp of double-stranded DNA to an import presequence and showed its uptake by isolated mitochondria. This strategy has not been refined sufficiently to allow the import of even a small gene, but holds great promise as an antisense strategy for blocking mutant mtDNA replication or transcription in heteroplasmic mitochondrial disorders. The first steps towards employing this strategy were demonstrated in vitro using a peptide nucleic acid (PNA) designed to bind in a sequence-specific manner to the region surrounding the MERRF (myoclonic epilepsy and ragged-red fibres) point mutation. 7 In this system, Taylor et al showed that DNA synthesis from a runoff replication template containing the MERRF mutation was specifically blocked by PNA binding, while the wild-type template, differing only by a single base pair, produced full-length replication products.
Exploitation of the specificity of PNAs as antisense agents is not a new idea for nuclear gene therapy and their unique amide backbone and resistance to nucleases may endow them with sufficient resilience to act as longterm antisense agents. One of the problems associated with PNAs is, however, the conflicting data concerning their cellular internalisation. Their neutral charge pre-cludes complex formation with cationic liposomes, thus limiting their delivery potential to cells.
In this issue of Gene Therapy, Chinnery et al 8 have considerably strengthened the case for an antisense strategy of mitochondrial disease by first demonstrating the uptake of biotinylated PNA into a variety of cell types, showing the cell specific variability and nuclear localisation in this uptake, and also suggesting that high concentrations are required to see successful internalisation. In a second series of experiments, Chinnery et al also show the import of PNA, coupled to the cytochrome c oxidase subunit VIII presequence, into the inner membrane or the matrix of isolated mitochondria and mitoplasts. They then go on to combine these two approaches and demonstrate uptake and mitochondrial localisation of peptide-PNA in cultured human myoblasts, derived from one of the tissue types most severely affected by mitochondrial myopathies. Biotinylated PNA internalised into myoblasts appears to localise to the nucleus, whilst the peptide-PNA added to these cells shows a distinct mitochondrial localisation.
Unfortunately, current methodology does not provide conclusive proof that the peptide-PNA has reached the mitochondrial matrix, which would be essential for its functionality. While Chinnery et al state that the attachment of the presequence to PNA does not affect its ability to bind DNA in vitro, it is worth re-examining the proposed models for protein (and thus peptide-PNA) import in this context, 4 since cleavage of the presequence may prove to be a vital component of successful import, to avoid stalling of the molecule across the inner mitochondrial membrane.
Importantly, the peptide-PNA used in this study is the same as used previously by Taylor et al to block replication of the MERRF template. The demonstration of functionality of this construct in vivo is clearly a desirable future goal and would allow the testing of this antisense system on the newly developing range of mouse models for mitochondrial disease heteroplasmy.
